SOURCE: Myriad Genetics

October 30, 2007 06:30 ET

Myriad Genetics Sponsors Dance-Theater Event Hosted by Alzheimer's Association, New York City Chapter

One-Time Only NYC Performance on November 2, 2007

SALT LAKE CITY, UT--(Marketwire - October 30, 2007) - Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it is sponsoring a unique dance-theater event titled, "Demolition Derby: when a mind loses its license to drive," hosted by the Alzheimer's Association, New York City Chapter on November 2, 2007.

The event is created by Erik Stern and portrays a son's experience caring for his parents who have dementia. There will be a panel discussion following the performance, with an opportunity for audience members to ask questions of Alzheimer's disease experts, patient advocates and Mr. Stern.

"We are very pleased to sponsor this powerful, engaging event," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "Dance provides a fascinating method of exploring the challenges for patients and their caregivers in dealing with the multitude of changes brought on by Alzheimer's disease."

"Caring for a loved one with Alzheimer's is demanding, exhausting and can negatively impact a person's health and well being," said Lou-Ellen Barkan, president and CEO of the Alzheimer's Association, New York City Chapter. "Often, caregivers suffer these consequences in silence and alone. I want to thank Erik Stern not only for his talent, but for sharing a deeply personal part of his life with us. I know this piece will resonate with everyone who sees it."

The New York City performance will be held at 6:30 p.m. at the Gerald W. Lynch Theater at John Jay College, 899 Tenth Avenue, between 58th and 59th Streets. Tickets are available through www.ticketweb.com, or by phone at (866) 468-7619. All proceeds go to the Alzheimer's Association, New York City Chapter.

Myriad Pharmaceuticals, Inc. is a subsidiary of Myriad Genetics, Inc., a biotechnology company focused on the development and marketing of novel therapeutic and molecular diagnostic products. The Company's lead drug candidate is Flurizan™, in clinical development for the treatment of Alzheimer's disease. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

Contact Information

  • Contacts:
    Myriad Genetics
    William A. Hockett
    EVP, Corporate Communications
    (801) 584-3600
    Email: Email Contact

    For the Alzheimer's Association, New York City Chapter:
    Kim Esp/Colleen Roche
    Linden Alschuler & Kaplan Public Relations
    212-575-4545
    Email Contact